Zacks Investment Research downgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a sell rating in a research report released on Wednesday, May 30th.
According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
CAPR has been the subject of several other reports. HC Wainwright reissued a buy rating and set a $9.00 price target on shares of Capricor Therapeutics in a report on Friday, May 11th. Maxim Group initiated coverage on Capricor Therapeutics in a report on Wednesday, May 16th. They set a buy rating and a $7.00 price target for the company. Finally, ValuEngine raised Capricor Therapeutics from a strong sell rating to a sell rating in a report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $4.91.
Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.03). The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.49 million. Capricor Therapeutics had a negative return on equity of 485.43% and a net margin of 110.98%. analysts forecast that Capricor Therapeutics will post -0.48 earnings per share for the current year.
A hedge fund recently bought a new stake in Capricor Therapeutics stock. Brown Advisory Inc. acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 1,136,755 shares of the biotechnology company’s stock, valued at approximately $1,796,000. Brown Advisory Inc. owned approximately 4.42% of Capricor Therapeutics at the end of the most recent reporting period. 4.01% of the stock is currently owned by institutional investors and hedge funds.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.